Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group

J. Moore, Malcolm; Goldstein, David; Hamm, John; Figer, Arie; R. Hecht, Joel; Gallinger, Steven; J. Au, Heather; Murawa, Pawel; Walde, David; A. Wolff, Robert; Campos, Daniel; Lim, Robert; Ding, Keyue; Clark, Gary; Voskoglou-Nomikos, Theodora; Ptasynski, Mieke; Parulekar, Wendy

doi:10.1200/jco.2006.07.9525

Public

Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group

Shared by NobleBlocks on May 20, 2007 • 12:00 AM UTC

Authors:

Malcolm J. Moore

David Goldstein

John Hamm

Abstract

Purpose Patients with advanced pancreatic cancer have a poor prognosis and there have been no improvements in survival since the introduction of gemcitabine in 1996. Pancreatic tumors often overexpress human epidermal growth factor receptor type 1 (HER1/EGFR) and this is associated with a worse prog...

Discussions